Mushroom-Derived drug targets kidney cancer in dialysis patients

NCT ID NCT05287945

First seen Jan 10, 2026 · Last updated May 10, 2026 · Updated 17 times

Summary

This early-phase trial tests a drug called orellanine in people with advanced kidney cancer who are also on dialysis. The goal is to see if the drug is safe and can shrink tumors. About 75 participants will receive the treatment, and researchers will monitor side effects and cancer response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Karolinska University Hospital

    RECRUITING

    Stockholm, Sweden

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • START Lisbon - Hospital de Santa Maria Av

    RECRUITING

    Lisbon, 1649-035, Portugal

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Stanford

    RECRUITING

    Palo Alto, California, 94304, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Texas - MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Washington University in St. Louis

    RECRUITING

    St Louis, Missouri, 63130, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.